Immunitybio (IBRX) has had the highest return this year and this year by a mid-cap US stock, returning 332.7%.
| ASSET | % RETURN |
|---|---|
Immunitybio (IBRX) | 332.67% |
Veradermics (MANE) | 323.09% |
Erasca (ERAS) | 303.77% |
MaxLinear (MXL) | 301.63% |
Pulse Biosciences (PLSE) | 301.16% |
Abcellera Biologics (ABCL) | 282.46% |
CareDx (CDNA) | 279.62% |
Okeanis Eco Tankers (ECO) | 260.97% |
Kodiak Sciences (KOD) | 259.73% |
AXT (AXTI) | 253.95% |
Hyperliquid Strategies Inc Common Stock (PURR) | 248.16% |
Iovance Biotherapeutics (IOVA) | 243.88% |
Absci (ABSI) | 240.85% |
Oruka Therapeutics (ORKA) | 218.87% |
Spyre Therapeutics (SYRE) | 202.08% |
Penguin Solutions (PENG) | 195.72% |
Enliven Therapeutics (ELVN) | 190.84% |
Ringcentral (RNG) | 190.27% |
PBF Energy (PBF) | 181.51% |
Definium Therapeutics (DFTX) | 181.19% |
International Seaways (INSW) | 170.2% |
Iridium Communications (IRDM) | 166.14% |
Maravai Lifesciences Holdings (MRVI) | 158.72% |
Lindblad Expeditions (LIND) | 158.51% |
Tango Therapeutics (TNGX) | 154.58% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.